Amazing?It's a Phase 2 trial, interim analysis
Efficacy
Injection-Free Rates: A significant portion of patients remained injection-free over the 26-week period, highlighting the potential of Ixo-vec to reduce the treatment burden associated with frequent ocular injections.
Visual Acuity: Patients maintained stable visual acuity, suggesting that Ixo-vec effectively controls the progression of wet AMD.
Where is the improved vision outcome? Without this how can it hold best-in-class treatment for wet AMD ?
Sozinibercept has the potential to improve vision for millions of patients with wet AMD.
If successful OPT could be heading towards new standard of care with best-in-class, is it not?
- Forums
- ASX - By Stock
- Opthea Media
Amazing? It's a Phase 2 trial, interim...
Featured News
Add OPT (ASX) to my watchlist
|
|||||
Last
37.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $409.3M |
Open | High | Low | Value | Volume |
37.5¢ | 37.5¢ | 37.0¢ | $922.2K | 2.465M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 262769 | 37.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
37.5¢ | 1 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 262769 | 0.370 |
3 | 31740 | 0.365 |
8 | 215184 | 0.360 |
3 | 24900 | 0.355 |
8 | 209029 | 0.350 |
Price($) | Vol. | No. |
---|---|---|
0.375 | 1 | 1 |
0.380 | 14940 | 1 |
0.385 | 14940 | 1 |
0.390 | 10000 | 1 |
0.400 | 42363 | 2 |
Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |